Pennsylvania Compounding Pharmacy Receives FDA Warning Letter
Decision brief
Answer first · skim in under a minute
On February 17, 2026, a Pennsylvania compounding pharmacy received another warning letter from the FDA, raising concerns over drug approvals and compliance. This development has significant implications for investors and pharmaceutical teams.
A Pennsylvania compounding pharmacy receives FDA warning letter scrutiny: on January 16, 2026, FDA cited Boothwyn Pharmacy, LLC in Kennett Square for serious sterile-production deficiencies after a May–June 2025 inspection.
Contents9 sections
Key Takeaways
- Warning Letter 717525 to Boothwyn Pharmacy, LLC (221 Gale Lane, Kennett Square, PA) is dated January 16, 2026.
- Inspection window: May 12 to June 9, 2025; Form FDA 483 issued June 9, 2025.
- FDA acknowledged a July 9, 2025 voluntary recall of within-expiry OOS lots and that the firm ceased sterile GLP-1 production, later notifying intent to resume.
- Older drafts that omitted the pharmacy name and used a February 17, 2026 date are corrected to the FDA letter.
Which Pennsylvania compounding pharmacy did FDA warn?
FDA’s Warning Letter 717525 is addressed to Boothwyn Pharmacy, LLC at 221 Gale Lane, Kennett Square, PA 19348. Investigators inspected the facility from May 12, 2025, to June 9, 2025 and said they found serious deficiencies in practices for producing drug products that put patients at risk.
Primary: FDA Warning Letter — Boothwyn Pharmacy, LLC (717525).
What corrective actions did FDA acknowledge?
FDA said it received facility responses dated July 1 and July 31, 2025. The agency also acknowledged that on July 9, 2025 the firm initiated a voluntary recall of all within-expiry drug products with out-of-specification results, including lots filled from the same bulk stock solution. FDA further noted the firm ceased production of all GLP-1 drug products intended to be sterile and, on August 20, 2025, notified FDA of intent to resume such production.
How does this connect to broader GLP-1 compounding enforcement?
The letter sits alongside FDA’s national messaging that semaglutide injection shortages are resolved and that compounders must meet 503A/503B conditions when making copies of approved products. Sterility and potency failures at a compounding site are a separate FDCA violation path from shortage discretion.
Policy context: FDA — GLP-1 compounding policy update.
What should pharmacy operators and investors watch next?
Operators should review OOS investigation SOPs, patient notification practices after failed sterility or potency tests, and airflow qualification of ISO 5 work zones. Investors in compounded GLP-1 channels should treat warning letters and recalls as binary operational risks, not marketing footnotes. Responses should reference Warning Letter Number 717525 when corresponding with FDA.
Quality leaders should also reconcile any “at risk” release practices against finished sterility results before restarting sterile GLP-1 lines.
What remains unproven?
This article does not restate every observation from unofficial blog digests as FDA fact unless present in the warning letter itself. It also corrects the prior February 17, 2026 date error. Patient-level harm counts that appear only in secondary summaries are omitted.
Related NovaPharma coverage
- FDA proposes weight-loss compounding rules
- FDA peptides bulk compounding
- FDA decision on compounded semaglutide
Frequently Asked Questions
Which Pennsylvania pharmacy received the January 2026 FDA warning letter?
Boothwyn Pharmacy, LLC in Kennett Square, Pennsylvania, received Warning Letter 717525 dated January 16, 2026, following a May 12–June 9, 2025 inspection.
What recall did FDA acknowledge in the Boothwyn letter?
FDA acknowledged that on July 9, 2025 the firm initiated a voluntary recall of all within-expiry drug products with out-of-specification results, including related bulk-filled lots.
Did Boothwyn stop sterile GLP-1 production?
FDA’s letter acknowledges the firm ceased production of all GLP-1 drug products intended to be sterile and later notified the agency on August 20, 2025 of an intent to resume production of such products.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
